Letrozole Glenmark

Letrozole, the active ingredient in Letrozole Glenmark, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women and works by selectively inhibiting the aromatase enzyme, reducing estrogen production that can fuel tumor growth.

GNH USA supplies Letrozole Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets and adhering to stringent international quality standards.

Letrozole acts on the estrogen synthesis pathway and is indicated for hormone‑dependent breast cancer.

- Hormone receptor‑positive breast cancer (postmenopausal): Reduces tumor progression by lowering estrogen levels. - Adjuvant therapy for early‑stage hormone receptor‑positive breast cancer: Decreases risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer (postmenopausal): Improves disease control in advanced disease settings.

Letrozole may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Joint and muscle pain: Discomfort in muscles and joints. - Fatigue: Persistent tiredness. - Nausea: Feeling of sickness. - Headache: Mild to moderate pain. - Dizziness: Light‑headed sensation.

Serious or Rare Side Effects: - Severe liver injury: Potential hepatic dysfunction. - Deep vein thrombosis or pulmonary embolism: Blood clot formation. - Bone fracture: Increased risk due to reduced estrogen. - Allergic reactions (anaphylaxis): Severe hypersensitivity. - Cardiovascular events: Heart‑related complications.

Before initiating Letrozole, several safety considerations should be reviewed.

- Monitor bone mineral density: Risk of osteoporosis and fractures. - Assess liver function: Potential hepatotoxicity requires periodic testing. - Evaluate cardiovascular status: Increased risk of thromboembolic events. - Avoid use in pregnancy: Classified as Category X due to teratogenic risk. - Store at ambient temperature below 25°C: Keep in the original pack, protect from moisture.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): May markedly reduce Letrozole effectiveness. - Tamoxifen: May antagonize the hormonal blockade. - Estrogen replacement therapy: Counteracts Letrozole’s action.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): May increase bleeding risk. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): May affect metabolism. - Statins: Possible alteration of plasma levels.